Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab.

G, Lurje; F, Nagashima; W, Zhang; D, Yang; HM, Chang; MA, Gordon; A, El-Khoueiry; H, Husain; PM, Wilson; RD, Ladner; DJ, Mauro; C, Langer; EK, Rowinsky; HJ, Lenz

doi:10.1158/1078-0432.ccr-07-5165

Public

Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab.

Shared by NobleBlocks on Dec 1, 2008 • 12:00 AM UTC

Authors:

Lurje G

Nagashima F

Zhang W

Abstract

<h4>Purpose</h4>Recently, an objective response rate of 12% was reported in a phase II study of cetuximab in patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer (mCRC) refractory to fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy (IMC-0144...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!